About 69,558 results

ALLMedicine™ Melanoma Center

Research & Reviews  23,195 results

Associations of coffee/caffeine consumption with postmenopausal breast cancer risk and ...
https://doi.org/10.1007/s00394-022-02899-8 10.1093/jn/136.1.166 10.1080/01635581.2013.768348 10.1002/ijc.29569 10.1186/s13058-015-0521-3 10.3390/nu10020112 10.1158/1055-9965.EPI-15-0246 10.1002/cncr.24328 10.1093/ajcn/84.1.95 10.1097/FPC.0b013e3283498ecf 10.1093/carcin/bgi206 10.1002/ijc.23336 10.1093/jnci/87.3.190 10.1002/ijc.11034 10.1093/jnci/djh336 10.1016/j.jsbmb.2007.05.012 10.1186/bcr767 10.1001/jama.295.21.2492 10.1158/1055-9965.EPI-10-0188 10.1038/modpathol.3800255 10.1073/pnas.191367098 10.1093/jnci/djh025 10.1186/bcr2261 10.1016/j.cdp.2005.07.004 10.1158/1055-9965.EPI-06-0806 10.1186/s13058-015-0521-3 10.1158/1078-0432.CCR-14-1748 10.3945/ajcn.115.120147 10.1016/S1047-2797(98)00055-6 10.1093/jnci/djt043 10.1093/gerona/glw078 10.1053/j.ajkd.2013.03.013 10.1097/01.ASN.0000031805.09178.37 10.1016/S1047-2797(03)00043-7 10.1080/01621459.1999.10474144 10.1002/sim.7501 10.1177/0962280206074463 10.1002/9780470316696 10.1080/10408398.2016.1247252 10.1007/s00394-019-02018-0 10.1093/oxfordjournals.aje.a116870 10.1017/S1368980011000371 10.1001/archinte.168.18.2022 10.1038/bjc.1994.258 10.1007/s10552-009-9396-x 10.1002/ijc.23336 10.1016/j.ajog.2008.10.019 10.1016/j.ygyno.2013.03.014 10.1007/s10552-018-1028-x 10.3945/ajcn.111.022533 10.1172/JCI37385 10.1017/S002966511100320X 10.1016/j.numecd.2015.05.005 10.1002/ijc.22717 10.1093/ajcn/87.5.1384 10.1093/ajcn/75.3.492 10.1158/1055-9965.EPI-15-0187 10.1093/ajcn/69.2.243 10.1093/oxfordjournals.aje.a114086 10.1007/s10549-018-4667-4
European Journal of Nutrition; Yaghjyan L, McLaughlin E et. al.

May 19th, 2022 - We investigated the association of coffee and caffeine with breast cancer (BCa) risk, overall and by ER/PR status. We also examined potential interactions of coffee and caffeine with postmenopausal hormone use. Our study included 77,688 postmenopa...

Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma...
Cancer Research; Bonfill-Teixidor E, Iurlaro R et. al.

May 19th, 2022 - The therapeutic benefit of approved BRAF and MEK inhibitors (BRAFi/MEKi) in patients with brain metastatic BRAF V600E/K-mutated melanoma is limited and transient. Resistance largely occurs through the restoration of MAPK signaling via paradoxical ...

Non-enzymatic function of WRN RECQL helicase regulates removal of topoisomerase-I-DNA c...
Aging Cell; Gupta P, Majumdar AG et. al.

May 19th, 2022 - Mutation in Werner (WRN) RECQL helicase is associated with premature aging syndrome (Werner syndrome, WS) and predisposition to multiple cancers. In patients with solid cancers, deficiency of the WRN RECQL helicase is paradoxically associated with...

Editorial of special focus on melanoma immunotherapy.
Human Vaccines & Immunotherapeutics; Rossi E

May 19th, 2022 - Editorial of special focus on melanoma immunotherapy.|2022|Rossi E,|

see more →

Guidelines  38 results

Clinical features, molecular characteristics and surgical management of primary penile ...
Melanoma Research; Cakir OO, Pozzi E et. al.

Nov 30th, 2021 - Penile mucosal melanoma is an aggressive and rare genital malignancy. The aim of the present study was to review the management and outcomes of a homogenous cohort of patients with histologically confirmed penile mucosal melanoma, at a single spec...

New Eye Cancer Therapy Shown to Target Cancer Cells, Spare Vision
American Academy of Ophthalmology

Nov 15th, 2021 - NEW ORLEANS, La. – Choroidal melanoma is a rare cancer that affects the back of the eye. If the tumor grows, it can cause the retina to detach, leading to vison loss. And if it spreads to other parts of the body, it can be fatal. There are no appr...

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Can...
Current Oncology (Toronto, Ont.); Thawer A, Miller WH et. al.

Oct 1st, 2021 - The combination of dabrafenib and trametinib is a well-established treatment for BRAF-mutated melanoma. However, the effectiveness of this approach may be hindered by the development of treatment-related pyrexia syndrome, which occurs in at least ...

Annual Report to the Nation: Rapid Decrease in Lung Cancer and Melanoma Deaths Lead Overall Continued Decline in Cancer Death Rate
American Cancer Society

Jul 8th, 2021 - Overall cancer death rates continue to decline in men and women for all racial and ethnic groups in the United States, according to the latest Annual Report to the Nation on the Status of Cancer. During 2001 to 2018, declines in lung cancer death ...

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.
Journal of the National Comprehensive Cancer Network : JN... Swetter SM, Thompson JA et. al.

Apr 13th, 2021 - Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways for treatment of microscopic satellitosis (added in v2.2020), and the following Principles sections: Molecular Testing (added in v2.2019), ...

see more →

Drugs  50 results see all →

Clinicaltrials.gov  1,007 results

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

May 13th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

May 13th, 2022 - Background: Metastatic digestive tract cancers, in particular esophageal, gastric, pancreatic and hepatobiliary carcinomas, are associated with poor survival beyond five years and poor response to existing therapies. Data from the National Cancer ...

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

May 13th, 2022 - Subjects must be diagnosed with melanoma. All subjects receive sentinel lymphadenectomy. If the subject is sentinel node positive and meets study requirements, the subject is randomized to receive either (1) completion lymphadenectomy (2) observat...

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

May 13th, 2022 - Background: Among the new cases of bile tract carcinoma (BTC) that are diagnosed every year in the United States, there are approximately 6,500 cases of gallbladder carcinoma, 3,000 cases of extrahepatic cholangiocarcinoma, and 3,000 cases of intr...

Validating Pain Scales in Children and Young Adults

May 13th, 2022 - Background: Pain is a common symptom among children with a variety of medical illnesses. Currently, a number of rating scales are used to assess pain interference and pain severity in adults. However, relatively few measures assessing these variab...

see more →

News  3,500 results

Study Hints at a Mechanism Behind Aggressive Melanoma

May 11th, 2022 - A mutation in a gene involved in chromatin remodeling is associated with aggressive melanoma, according to a new study that combined in vitro and animal model data. The gene, ARID2, is a part of the switch/sucrose nonfermentable (SWI/SNF) complex,...

Substantial Medical Debt, Bankruptcy Linked to Thyroid Cancer

May 9th, 2022 - Patients with thyroid cancer may experience greater financial challenges compared to those with other common cancers, a recent review suggests. Researchers found, for instance, that patients with thyroid cancer had higher total yearly healthcare e...

Nivolumab Plus PD-L1/IDO Peptide Vaccine Displays Impressive Efficacy in Metastatic Melanoma

May 5th, 2022 - Nivolumab (Opdivo) in combination with a PD-L1/IDO peptide vaccine displayed encouraging efficacy and survival results among patients with metastatic melanoma, according to data from a phase 1/2 trial (NCT03047928) presented at the 2022 AACR Annua...

SOT101 Plus Pembrolizumab Elicits Encouraging Efficacy in Advanced Solid Tumors

May 2nd, 2022 - The addition of SOT101, an interleukin (IL)-2/IL-15 Rβγ superagonist, to Pembrolizumab (Keytruda) generated a clinical benefit and encouraging safety data in patients with advanced solid tumors, according to data presented at the 2022 AACR Annual ...

Sotigalimab Plus Pembrolizumab Elicits Broad Immune Activity in Metastatic Melanoma

May 2nd, 2022 - The combination of the CD40 agonist antibody sotigalimab (APX005M) and pembrolizumab (Keytruda) demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III o...

see more →

Patient Education  33 results see all →